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Abstract Neurofibromatosis type 1 (NF1, von Recklinghausen disease) is inherited in 
autosomal dominant way genetic disorder, with an incidence at birth 1:3000. It is 
one of the most common congenital disorders. It is characterized by café-au-lait 
spots, neurofibromas, and less common MPTST and gliomas of the optic nerve. It 
is caused by germline mutations of the NF1 gene, which acts as tumor suppressor. 
Inactivation of the gene leads to increased activation of the kinase pathways, and 
in consequence, uncontrolled proliferation of cells. The disease predisposes to the 
development of both benign and malignant tumors. Malignant tumors, but not 
related to the nervous system occur in neurofibromatosis quite rare. The aim of 
the study is a literature review of NF1, with presentation of a patient with NF1 and 
coexisting numerous tumors: synchronous somatostatinoma and gastrointestinal 
stromal tumor with metachronous prostate adenocarcinoma and non-small cell 
lung carcinoma. And attempt to answer the question if there is a common pathway 
for oncogenesis of these four tumors. 
Abbreviations:
KIT(CD117) and CD 34  - clusters of differentiation markers of stem cells
Cdc42/Rac-PAK1 - p21 protein (Cdc42/Rac)-activated kinase 1
CT - computed tomography
GIST - Gastrointestinal stromal tumor
MAP(MAPK) - mitogen-activated protein kinases
MPNST - malignant peripheral nerve sheath tumor
MRI - magnetic resonance imaging
mTOR - mammalian target of rapamycin kinase
NF1  - neurofibromatosis type 1
NSCLC - non-small cell lung carcinoma
p21-RAS - p21 protein activator 1
PDGFRA - platelet-derived growth factor receptor A
PET/CT - positron emission tomography combined with computed tomography
PTH  - parathyroid hormone
RAS-MAPK  - The Ras/mitogen activated protein kinase
RET - receptor tyrosine kinase
TP53 - tumor protein 53
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INTRODUCTION
Neurofibromatosis type 1 (NF1) is an inherited in an 
autosomal dominant pattern disease with prevalence 
1:4000–1:5000, caused by mutation in tumor suppres-
sor gene NF1, located on chromosome 17q11 (Ferner 
2007; Friedman et al. 1998).
The product of the gene – neurofibromin is a cyto-
plasmic protein, acting through an inactivation of p21-
RAS protein and in an advance – downregulation of 
kinase pathways – mTOR and MAP, which transduce 
signals from cell membrane to the nucleus (Brems et 
al. 2009; Gottfried et al. 2010). Constant activation of 
this pathways results in increased proliferation of cells 
(Brems et al. 2009).
NF1 is characterized by flat skin lesions – café-au-lait 
spots, numerous neurofibromas of the skin, freckling in 
the axillary and groin area, gliomas of the optic nerve 
and musculoskeletal lesions. Patients with NF1 have 
an increased risk of developing benign and malignant 
tumors (malignant tumors are found in 3–15% of those 
patients). Life expectancy in patients with NF1 is about 
15 years shorter than in general population. The main 
causes of deaths are malignant tumors (Rasmussen et al. 
2001; Seminog & Goldacre 2013). 
Co-existence of multiple malignancies with NF1 has 
not been reported much in literature. An example of the 
occurrence of this type of disorder in a single patient is 
presented below.
CASE REPORT 
In May 2003, 46-year old male patient with diagnosed 
15 years before NF1 was admitted to the Clinical 
Department of Endocrinology at the University Hospi-
tal for further diagnosis.
NF1 was diagnosed based on clinical appearance 
(café-au-lait spots, multiple neurofibromas of skin and 
spinal canal, Lisch nodules) and positive family history 
(father and brother of the patient had NF1).
In November 2002 patient was hospitalized in The 
Department of General, Oncological and Gastroen-
terological Surgery at the University Hospital because 
of acute pancreatitis. Computed tomography (CT) and 
ultrasound of the abdomen revealed pathological mass 
in the head of the pancreas, with heterogenous echo-
structure, 45 mm in diameter. In December 2002 patient 
was again admitted because of cachexia, with symptoms 
suggesting stenosis of duodenum and tumor of pancreas. 
He underwent pancreatoduodenectomy with simulta-
neous cholecystectomy. Histopathological examination 
of excised tissues revealed ganglioneuromatosis of the 
mucosa of duodenum, ectopic pancreas with the pres-
ence of neuroendocrine tumor cells (positive staining for 
somatostatin). Within somatostatinoma nodule (15 mm 
in diameter) there was no mitotic activity. Additionally, 
on the mucosa of the duodenum there were found 2 
nodules, one of which was diagnosed as neurofibroma, 
and second one (10 mm in diameter) was recognized as 
gastrointestinal stromal tumor – GIST (positive staining 
for CD117 protein). During first hospitalization in the 
Department of Endocrinology patient underwent whole 
body scintigraphy with somatostatin analogue, ultra-
sound and scintigraphy of the thyroid gland. Except of 
small, benign nodules of thyroid (with no clinical sig-
nificance) there were no pathological findings. 
In 2004 laboratory test showed elevated concen-
tration of parathormone (PTH) with hypocalcemia, 
low Vitamin D and normal phosphate concentration. 
Repeatedly conducted 99mTc-sestamibi scintigraphy 
revealed no pathological uptake within parathyroid 
glands. According to this, secondary to the malabsorp-
tion of calcium and vitamin D after pancreatoduo-
denectomy hyperparathyroidism was diagnosed. In 
January 2008, another whole-body scintigraphy with 
somatostatin analogue was performed. It showed only 
tracer uptake within skin lesions in the lower part of 
the trunk (in the place of neurofibromas). In June 2009, 
because of reported recurring short episodes of visual 
lost, magnetic resonance imagining (MRI) was con-
ducted. It revealed the 16×8 mm extension of the left 
optic nerve in retrobulbar part suggesting glioma. More-
over, it revealed neuroma of auditory nerve in the prox-
imal part of the right internal acoustic meatus. During 
the follow-up period the changes remained stable. 
In 2010 genetic screening for mutations within pro-
tooncogen RET and antioncogen MEN1 was performed 
– no mutations were found. Because patient met the cri-
teria of the National Institute of Health, no genetic test 
was conducted to find mutations in NF1 gene. 
In the meantime, due to occurrence of symptoms 
from gastrointestinal tract (diarrhea, presence of fresh 
blood in the stool) colonoscopy was performed three 
times. During the first two, polyps were excised (in 
2011 and 2013). In March 2014 CT of abdomen and 
pelvis showed circular infiltration of the transverse and 
splenic flexure of the colon. But no pathological changes 
were seen on the performed colonoscopy in April 2014.
At the same time, in March 2014, patient was diag-
nosed with adenocarcinoma of prostate (in right lobe 
– adenocarcinoma Gleason 2+3; in the left lobe – ade-
nocarcinoma, Gleason 3+2).
While qualifying for prostatectomy, imaging studies 
of the chest revealed a nodular change in the left lung. 
Extended diagnostics (PET/CT) confirmed the pres-
ence of the change in the left lung and revealed a second 
one, smaller, in the right lung. Based on the examina-
tion of the material obtained from a biopsy, a diagnosis 
of non-small cell lung carcinoma (NSCLC) of the left 
lung with dissemination to the right lung (carcinoma 
planoepitheliale nonkeratoticum GI/GII CK 5/6+, 
p63+, PSA–) was made. 
In January 2015, the patient began palliative che-
motherapy (navelbine+cisplatin: DDP+NVB). Unfor-
tunately, despite treatment disease progressed. Patient 
died in May 2015 at the age of 56.
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DISCUSSION
The most important question that arises in connection 
with the case presented, is the question of the relation-
ship between NF1 and tumors, which occurred in the 
patient described. Besides neurofibromas, NF1 patients 
are at increased risk of developing benign and malig-
nant tumors. These are mainly tumors derived from 
neural tissue, such as malignant tumor of the periph-
eral nerve sheath (MPNST), glioma or astrocytoma 
(Gottfried et al. 2010; Kiuru & Busam 2017; Seminog & 
Goldacre 2013; Zöller et al. 1997).
The frequency of abdominal tumors in patients 
with NF1 in recent studies varied significantly (5% 
up to 25% (Basile et al. 2010; Cavallaro et al. 2010; 
Fuller&Williams 1991; Heuschkel et al. 2001). 
GIST is believed to be derived from Cajal interstitial 
cells (Gopie et al. 2018; Sircar et al. 1999). Incidence is 
estimated at around 15–16 cases/million/year. Most of 
them are found in the stomach and small intestine. The 
most characteristic is the expression of KIT (CD117) 
and CD34 proteins (which are used as diagnostic crite-
ria) in those cells. The risk of malignant transformation 
increases with the size of the tumor and mitotic activ-
ity (Miettinen et al. 2002). GIST does not give specific 
symptoms. The most common manifestations are non-
specific abdominal pains, symptoms of obstruction or 
bleeding from the gastrointestinal tract (And ersson et 
al. 2005; Giuly et al. 2003). 
GIST is the most common neoplasm of the diges-
tive tract in patients with NF1 (up to 25% of patients in 
autopsy studies) (Ghrist 1963; Zöller et al. 1997). In one 
study, 1.5% of GIST were related to NF1 (Miettinen et 
al. 2006). Higher prevalence of NF1 gene mutations in 
GIST patients (up to 50–150-fold increased risk) was 
shown also in works by Cheng and Andersson inde-
pendently (Andersson et al.2005; Cheng et al. 2004). 
What is more, some authors in their papers stressed the 
differences between sporadic and NF1-related GISTs 
(as for NF-1 related GISTs: lack of KIT and PDGFRA 
mutations, lower mitotic counts, localization in small 
intestine, presentations as multiple tumors, indolent 
nature) (Andersson et al. 2005; Nishida et al. 2016; 
Wada et al. 2016).
Fig. 1.  SPECT images (2008). Tracer uptake within skin lesions in the 
lower part of the trunk (in the place of neurofibromas). 
Fig. 2. PET Image (2014). Tumor of the left lung with dissemination 
to the right lung (black arrows). Neurofibroma of right tigh (red 
arrow). Metabolically active site in the prostate (green arrow).
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The pathogenesis of this nonendocrine tumor in 
NF1 is not fully known. The hypothesis put forward by 
Stewart et al. indicating the role of loss of heterozygos-
ity in NF1 gene with the absence of KIT and PDGFRA 
mutations (as opposed to sporadic GIST) seems to be 
acceptable. Studies performed by other authors gave 
similar results (Andersson et al. 2005; Kinoshita et 
al. 2003; Steward et al. 2007; Yamamoto et al. 2009). 
According to Suzuki et al. (2004), the fact that the 
mutation responsible for NF1 concerns the tumor sup-
pressor gene, increases the risk of nonneuroendocrine 
malignancies. 
There are conflicting reports regarding response to 
tyrosine kinase inhibitors-imatynib mesylate in NF-1-
related GISTs (because of mentioned above absence 
of KIT and PDGFRA mutations). Some authors (Lee 
et al. 2006) – reported favorable effect, while others 
(Mussi et al. 2008; Nikishita et al. 2016) suggested 
that there was or would be no response to imatynib 
mesylate.
Somatostatinoma is a rare neuroendocrine tumor 
with an incidence of 1/40 million/year. However, in 
patients with NF1 somatostinoma is the most common 
neuroendocrine tumor, occurring in over 40% of all 
patients (House et al. 2002; Nesi et al. 2008; Steward et 
al. 2007; Tanaka et al. 2000; Teixeira et al. 2016).
Most of these tumors are located in the pancreas 
(68%), less often in the duodenal papilla of Vater or 
small intestine. Only in two cases described before year 
2009, somatostatinoma was found in ectopic pancreas 
(Gottfried et al. 2010; Miettinen et al. 2006).
The literature highlights the frequent occurrence of 
typical symptoms, in case of somatostatinoma localised 
in the pancreas (Nesi et al. 2008), while less common in 
other locations, which is confirmed in the present case. 
Classic triad of somatostatinoma/inhibitory syndrome, 
manifested by diarrhea, diabetes and cholelithiasis can 
greatly facilitate the diagnosis. Clinical manifestation of 
somatostatinoma localised in the duodenum is unspe-
cific and rarely associated with the typical syndrome, 
which is why this unit is often detected by chance. In 
paper by Cappelli et al. they observed, that NF-1-re-
lated somatostatinoma rarely was producing hormones 
(Capelli et al. 2004).
Somatostatinoma is malignant in 60–70% of cases, 
and the risk of metastasis increases with the diameter 
of the tumor. The diameter of 2 cm is regarded as cut-
off value, above which significantly increases the risk 
of metastases (Nesi et al. 2008; Tanaka et al. 2000). In 
the present case, the diameter of somatostatinoma was 
15 mm, and metastases during the entire period of 
observation of the patient were not observed. 
The fact that duodenal tumors are generally smaller, 
less impact on their malignant potential than their coun-
terparts in the pancreas. By Mao et al. (1995), almost 
30% of somatostatinoma localised in duodenum and 
70% of pancreatic somatostatinoma, metastases occur 
at the time of diagnosis. This prompts the question of 
the relationship between the diameter of somatostati-
noma occurring in ectopic pancreas in the duodenum 
and the risk of metastasis. It seems that because they are 
more similar to the dimensions of duodenal tumors, so 
they give a better prognosis. 
Until recently, it was believed that the simultaneous 
occurrence of somatostatinoma and GIST is an excep-
tional and rare case. However, in recent years there have 
been more and more reports about the coexistence of 
those tumors in patients with NF1 (Abdessayed et al. 
2017; Bettini et al. 2007; Karatzas et al. 2000; Kumar et 
al. 2016; Njei & Sanchez 2014; Rasmussen et al. 2001; 
Relles et al. 2010; Suzuki et al. 2004; Teixeira et al. 2016; 
Tewari et al. 2014; Yamamoto et al. 2016). These neo-
plasms are revealed in older age than skin changes. The 
presented case of coexistence of somatostatinoma and 
GIST in a patient with NF1 may constitute evidence of 
a common genetic path of formation of both tumors 
on the ground of a mutation. By Barahova-Garrido et 
al. (2009), there is a close link between mesenchymal 
tumors and neuroendocrine tumors suggesting the exis-
tence of a “common path”. By Johannessen et al. (2008), 
the following transduction pathways which influence 
the development of malignant tumors (among them 
also GIST and somatostatinoma) are taken into account 
in patients with NF-1: RAS-MAPK, mTOR and Cdc42/
Rac-PAK1.
Although lung carcinoma is significantly more 
common in patients with NF1 (Hsu & Hsu 2015; Kim et 
al. 2012; Seminog & Goldacre 2013; Walker et al. 2006), 
it`s pathogenesis is not fully understood. 
One of the proposed theories, is that of the role of 
a scar tissue in the lung tumorigenesis (Shimizu et al. 
1994). According to this theory, interstitial fibrosis, and 
emphysema changes which are seen in patients with 
NF1 (Casal et al. 2018, Reviron-Rabec et al. 2016; Ueda 
et al. 2015) are risk factors for lung cancer. Changes in 
the lung tissue in the course of NF1 would be equal to 
those observed in cigarette smokers. This has not been 
finally confirmed (Casal et al. 2018; Ryu et al. 2005) – 
the changes have also been reported in non-smoker 
NF-1 patients. The X-ray and CT of the lungs in our 
patient reported disseminated fibrosis and numerous 
emphysema blisters. What is more, patient was for 
many years a smoker of tobacco and for several years 
worked in exposure to asbestos. 
It is not possible to distinguish changes arising in 
the course of smoking from those secondary to NF1. 
Studies by Shimizu et al. (1994) and Ryu et al. (2005), 
reported on the development of emphysema changes in 
younger patients with NF1. The authors suggested that 
genetic predisposition (NF1 mutation) in combination 
with active smoking drove to the earlier development 
of cancer.
According to the second theory of oncogenesis of 
lung carcinoma, mutation in a suppressor gene TP53 
(which is also located on chromosome 17 as NF1 gene) 
takes participation. Coexistence of inactivating muta-
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tions in the gene TP53 and in NF1 was associated with 
more severe NF1 (Menon et al. 1990; Upadhyaya et al. 
2008). The relation between carcinoma of the lung and 
inactivation of p53 was revealed previously. Moreover, 
in smokers compared to non-smokers, there are more 
frequent mutations in TP53 (Husgafvel-Pursiainen et 
al. 2000; Takagi et al. 1998).
So far only one case has been previously reported of 
co-occurrence of prostate carcinoma with NF1. Araki 
et al. in 1983 reported the case of 65-year-old patient 
with NF1, diagnosed with adenocarcinoma of the 
prostate. Moreover, until recently, no relationship was 
found between the NF1 and prostate carcinoma as well 
as between carcinoma of the prostate and other tumors 
described above. In population-based study, Seminog 
& Goldacre did not found significantly elevates risks 
for prostate carcinoma (17 cases observed, expected-23, 
p-value 0.444) (Seminog & Goldacre 2013). Probably 
changes in RAS/RAF and mTOR signaling pathway, 
which are observed both in prostate cancers as well as 
NF1-patients can play a crucial role in the development 
of both types of cancer. (Stelloo et al. 2016; Taylor et al. 
2010).
It seems likely that the solitary germline mutation in 
the NF1 gene is not sufficient to oncogenesis. Accord-
ing to the Knudsons` two hit hypothesis, only in the 
case of somatic mutation of the second allele of the 
gene, there is a disclosure of a tumor (Knudson 1971). 
Perhaps there are a few common pathways for various 
groups of tumors. Frequent co-occurrence of GIST and 
somatostatinoma suggests a common pathway. In the 
case of lung cancer, it appears to be correct the theory 
on the impact of mutations in tumor suppressor gene 
TP53. Moreover, the co-existence of the inactivating 
mutations in the gene of p53 mutations in NF1 was 
associated with more severe NF1 (Upadhyaya et al. 
2008) and combined with premature mortality (Ras-
mussen et al. 2001; Seminog & Goldacre 2013). 
In l iterature where mostly presented cases with co-
existence of somatinoma and GIST in NF1 patients. 
Co-existance of more than 2 malignancies is extremely 
rare. Nevertheless, the NF1 patients with two malig-
nancies should be under strict oncological control. 
CONCLUSIONS
1. Patients with NF1 should be under special oncologi-
cal alertness, as changes in the course of the underly-
ing disease can mask the presence of other neoplastic 
lesions, including malignant ones.
2. Patients with NF1 who present gastrointestinal 
symptoms should arouse increased alertness and be 
observed for duodenum and pancreas tumors. 
3. Deeper understanding of genetic and molecular 
pathways of oncogenesis will allow a better under-
standing of the pathophysiology of tumors coex-
isting with NF1 and may give a chance to more effec-
tive, targeted treatment.
4. Given the poor prognosis in patients with lung carci-
noma, patients with NF1, in particular with changes 
indicative of fibrosis of the lung tissue, require 
special careful observation for the emergence of 
carcinoma.
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